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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is
Platelet-Rich Plasma (PRP) a more effective treatment in reducing pain than corticosteroid (CS)
injections in musculoskeletal injuries?”
STUDY DESIGN: Review of three, double blind, randomized controlled trials (RCTs),
published between 2013 and 2016, all in the English language were included. The articles
compared platelet-rich plasma (PRP) and corticosteroid (CS) injections to a visually matched
placebo of saline in regard to reduction of pain from baseline in varying different
musculoskeletal injuries.
DATA SOURCES: Three RCTs were found using PubMed and Google Scholar. All articles
were published in peer reviewed journals and selected based on their correlation to the topic of
choice, the date of publication, and their ability in evaluating POEMs.
OUTCOMES MEASURED: Patient reported pain level, as measured by visual analog scale
(VAS) score as well was joint specific scoring, such as the Patient-Rated Tennis Elbow
Evaluation (PRTEE).
RESULTS: Forogh et al. and Mahindra et al. determined that both PRP and CS injections
significantly reduced pain in knee osteoarthritis and chronic plantar fasciitis, respectively.
However, Forogh et al. concluded that PRP had significantly better outcomes at 2 and 6 months
follow up. Mahindra et al. concluded that CS injections had better outcomes at 3 weeks and 3
months follow up, whereas, PRP injections showed better outcomes at 3 months follow up.
Krogh et al. determined that there was no significant difference in pain reduction comparing CS
and PRP injections to a placebo injection.
CONCLUSION: Based off the data collected from the three RCTs, it is inconclusive whether
platelet-rich plasma is a more effective treatment that corticosteroid injections in musculoskeletal
injuries.
KEYWORDS: Platelet-Rich Plasma, Corticosteroids, Musculoskeletal Injuries
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INTRODUCTION
Musculoskeletal injuries are very prevalent causes of morbidity in the United States
today. Many of these injuries can be attributed to the elder population and may include
osteoarthritis and falls.1 The most common cause of injury in the youth population can be
attributed to trauma such as motor vehicle accidents and sports injuries.1 There are many
different mechanisms, pharmacological therapies, and procedures that may be used to treat
varying different musculoskeletal injuries. Treatment may be based on the part of the body
injured or the structure of the body that has been injured.
Musculoskeletal injuries can be defined as any condition or injury that affect the bones,
joints, or muscles.6 These can be painful, even debilitating, and can affect the everyday quality of
life, activity, and productivity in these individuals. Over 6.8 million United States residents
sought out medical care due to musculoskeletal related injuries in 2012.1 Of these reported
statistics, injuries most commonly occurred in the 18-64-year-old age range with sprains and
strains accounting for a majority of these injuries.1 Arthritis is the most common cause of
disability, with approximately half of the United States population over the age of 65 being
affected by this condition.6 In the year of 2011, the cost burden of these such musculoskeletal
injuries in the United States costed approximately $213 billion.6 Per person, the total cost for
medical treatment of a musculoskeletal condition averaged about $47, 800 in 2011.6
Furthermore, approximately 18% of all healthcare visits were related to musculoskeletal
conditions in 2010.6 Musculoskeletal injuries are clearly a significant contributor to healthcare
costs and prevalence today.
Due to the commonality of musculoskeletal injuries, there are numerous modalities used
in the treatment of such conditions. Several studies have been completed in the comparison of
PRP and CS injections with varying outcomes depending on the injury and length of time of
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treatment.3,4,5 For example, one study on plantar fasciitis found that PRP was more effective long
term compared to CS, however, another study found that there was no significant difference in
the outcomes comparing PRP to CS.7,8,9 Other treatment modalities have also been used
commonly in the treatment of musculoskeletal injuries. These treatments can include other types
of injections, including hyaluronic acid, also physical therapy or occupational therapy,
acupuncture or acupressure, osteopathic manipulation, chiropractic care, and therapeutic
massage, or a combination of these. The decision regarding the treatment modality may be
provider preference, age, and involved body part of injury.
A common treatment for varying musculoskeletal injuries is the use of corticosteroid
(CS) injections as well as an emerging treatment modality for these injuries is the use of plateletrich plasma (PRP) injections. Platelet-rich plasma aids in the healing of injured tissues due to its
introduction of increased concentrations of growth factors as well as bioactive molecules which,
therefore, creates an optimized healing environment.2,3 The growth factors included have effects
on cell proliferation, chemotaxis, cell differentiation, and angiogenesis.4 These injections have
recently been used to aid in wound and bone healing, alloplastic surgeries, as well as healing
muscle and tendon damage.4 Intra-articular corticosteroid injections are historically and
frequently used in the treatment of acute as well as chronic inflammatory conditions.3
Corticosteroid anti-inflammatory properties are a result of the inhibition of anti-inflammatory
cytokines that block their pathway that leads to the inflammatory actions.3 The effectiveness of
both of these treatment modalities have been compared in various studies including plantar
fasciitis, lateral epicondylitis, and knee osteoarthritis, as well as many other musculoskeletal
injuries.3,4,5
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not, “Is Platelet-Rich
Plasma (PRP) a more effective treatment in reducing pain than corticosteroid (CS) injections in
musculoskeletal injuries?”
METHODS
Articles were found using PubMed and Google Scholar. Three randomized controlled
trials were used in this review. Patients older than 18 years of age with a diagnosed
musculoskeletal injury based on the specific injuries’ criteria were utilized in this study. The
experimental intervention was platelet-rich plasma injections and corticosteroid injections. The
control utilized were injections of normal saline.4,5 The reduction of pain from baseline in
patients receiving PRP injections compared to CS injections were compared at different intervals
in time as well as compared to various different musculoskeletal injuries. The outcome
evaluated in all three studies was the efficacy in reduction of pain when PRP injections were
used compared to the reduction of pain with CS injections, as demonstrated by the visual analog
scale (VAS) score in addition to injury specific pain scores.
All randomized controlled trials were published in peer reviewed articles, written in the
English language, and found on PubMed or Google Scholar databases. The keywords used in the
searches were “platelet-rich plasma,” “corticosteroid,” and “musculoskeletal injuries.” The
articles were selected based on relevance and that the outcomes of the studied mattered to the
patients (POEMs). The inclusion criteria were studies that were RCTs published after the year
2007. Exclusion criteria included patients under the age of 18 years old, those that did not have a
diagnosed musculoskeletal injury, patients that did not respond to conservative therapy, and
patients whom have received previous treatment for these injuries with PRP or CS injections.
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Table 1: Demographics and Characteristics of Included Studies
Study

Type

# Pts

Age
(yrs)
61.1±
7.0

Inclusion
Criteria
-Pain intensity
a ≥60 in the
VAS at the
time of
admission
-Pain >3 mo
-Undergoing at
least 2 OA
treatments
with no benefit

Forogh1

RCT

41

Mahindra2

RCT

75

30.7 ± -Heel pain and
7.42
tenderness of
calcaneal
33.9 ± tuberosity
8.61
-No response
to 3 mo of
35.4 ± conservative
9.54
therapy

Krogh3

Dou
ble
Blin
d
RCT

60

>18

-LE symptoms
for >3 mo
-US with signs
of
tendinopathy
of at least
grade 2
assessed at
baseline

Exclusion
Criteria
-History of
collagen
vascular, CV
diseases, DM,
cancer,
immunosuppres
sion, Hep B or
C, knee
injections,
infection,
arthroscopy or
surgery, active
lumbosacral
radiculopathy,
or drug abuse
-Use of NSAID
within 1 week
of injection

W/D

Interventions

2

-PRP: 20 mL
whole blood,
2 mL ACDA,
centrifuged or
12 mins at
1600 and
2000
-CS: 40 mg
of
methylpredni
solone acetate

0

-CS: 40 mg
methylpredni
solone
-PRP: 27 mL
whole blood
with 3 mL of
citrate
dextrose
centrifuged
for 12 mins at
3200rpm
-Normal
saline

-<18 yo
0
-CS injection
within the past
3 mo
-Previous tennis
elbow surgery,
inflammatory
diseases, neck
pain, shoulder
pain, and other
chronic
widespread
pain syndromes

-CS: 1 mL
triamcinolone
40 mg/mL
-Saline: 3 mL
saline 0.9%
-PRP: 27 mL
of whole
containing 3
mL sodium
citrate,
centrifuged
for 15 mins at
3200rpm

4
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OUTCOMES MEASURED
The primary outcome measured in all three studies was change in pain on visual analog
scale score or injury specific questionnaire from individual baseline. On this scale, patients are
able to rate their pain on a scale of 0 (no pain) to 10 (worst pain ever experienced). Forogh et al
utilized the 20-meter-walk test, active and passive knee range of motion, and flexion contracture
before the injections and again after injection for knee osteoarthritis.3 Mahindra et al.
incorporated the American Orthopaedic Foot and Ankle Society (AOFAS) and Hindfoot score to
evaluate chronic plantar fasciitis.4 Krough et al. utilized the Patient-Rated Tennis Elbow
Evaluation (PRTEE) questionnaire to allow patients to evaluate their pain.5
RESULTS
Two studies compared the efficacy of PRP injections and CS injections to a placebo.4,5
One study compared the efficacy of PRP directly to CS injections.3 Each study assessed the pain
for each specific injury at baseline before treatment was given.3,4,5 Forogh et al. evaluated the
intervention at 2 months, and 6 months, Krogh et al. evaluated the intervention at 3 months, 6
months, and 12 months, and Mahindra et al. evaluated the intervention at 3 weeks and again at 3
months.3,4,5 All three studies were double-blinded studies comparing the effectiveness of PRP
and CS injections in musculoskeletal injuries.3,4,5
The study conducted by Forogh et al. comparing platelet-rich plasma versus
corticosteroid injections in knee osteoarthritis was conducted in Tehran, Iran at the Physical
Medicine and Rehabilitation Clinic in Firouzgar Hospital.3 Inclusion and exclusion criteria for
this study can be found in Table 1. Forogh et al. evaluated 48 knees in 41 patients with 24 knees
divided evenly into the PRP injection group and CS injection group evenly.3 Of the initial 41
patients and 48 knees, 2 patients were lost to follow-up and four patients were excluded due to
seeking other treatment modalities, leaving a total of 39 knees being included in the statistical
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analysis.3 The PRP was prepared by drawing 20 mL of autologous blood with the addition of
anticoagulant citrate dextrose solution, Solution A. This then went through two centrifuge
procedures at 1600 relative centrifugal force (RCF) for 6 minutes and then 2000 RCF for 6
minutes, which produced 5 mL of PRP.3 This solution was activated by combining 0.5 mL of
calcium gluconate.3 One mL of Depo-Medrol containing 40mg of methylprednisolone was
utilized for the CS group.3 Efficacy was evaluated based on the patient reported VAS-based pain
intensity, 20-meter-walk test, as well as active and passive range of motion.3 Results were
calculated based on the change from baseline pain, pain at 2 months, and pain at 6 months
following the injection.3 This data indicated that platelet-rich plasma treatment significantly
relieved pain at both 2 months and 6 months follow-up, whereas, the corticosteroid treatment
was only effective in relieving pain at the 2 month follow-up. Statistical significance was set at
p<0.05 in this study.3 One patient reported dissatisfaction following the PRP injection due to
increased knee and lumbar pain.3 No other adverse events were reported by participants in this
study.3
Table 2: Efficacy in Pain Reduction Evaluated by Mean Change in VAS in Forogh et al.
Baseline
2-month
6-month
p-value
Platelet-Rich
81.3 ±13.4
45.1±23.4
44.6±15.6
<0.05
Plasma (N=23)
Corticosteroid
77.8±13.8
65.3±19.3
72.5±16.2
<0.05
(N=16)
Krogh et al. conducted their study comparing the pain efficacy of PRP and CS injections
to a placebo in patients with lateral epicondylitis (LE) in Denmark in the Rheumatology Unit at
the Region Hospital Silkeborg after patients were referred by general practitioners,
rheumatologists, or orthopaedic specialists.4 Patients included and excluded in this study can be
found in Table 1. The primary efficacy outcome was changes in intensity of pain 3 months after
the injection using the Patient-Rated Tennis Elbow Evaluation (PRTEE) questionnaire that
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evaluates pain as a score ranging from 0 to 50 points.4 Three months was the chosen length of
time evaluated due to the fact that the study gave patients the option to withdraw from the trial if
they did not achieve a satisfactory treatment response at 3 months.4 Sixty patients with LE were
included in the study and randomly divided with 20 patients in each arm of the study.4 Each
injection was ultrasound guided with the elbow bent at 90 degrees.4 The PRP was prepared using
27 mL of autologous blood mixed with 3 mL of sodium citrate, then centrifuged at 3,200 RCF
for 15 minutes.4 The CS group was injected with 1mL containing 40mg of triamcinolone and the
placebo injection consisted of 3 mL of saline.4 After 3 months Krogh et al. determined there was
no significant difference in pain reduction between any of the groups.4 However, at the one
month evaluation, CS showed significant improvement in pain compared to the PRP and saline
placebo groups.4 Due to the large number of drop out participants at 6 and 12 months, these
results were not included in the study.4 There were no serious adverse events in any of the groups
with no reports of infections after any injection therapies received.4
Table 3: Efficacy in Pain Reduction Evaluated by Mean Change in PRTEE in Krogh et al.
Baseline
Pain at 1 month Pain at 3 months Confidence
Interval (CI)
Platelet-Rich
27.5
-0.5
-6.0
95%
Plasma
Corticosteroid
28.0
-9.8
-7.1
95%
Saline (placebo) 25.0
-1.7
-3.3
95%
Mahindra et al. conducted their study comparing the efficacy in pain reduction of chronic
plantar fasciitis using PRP, CS, and a placebo injection in India at the Department of
Orthopaedics, Dayanand Medical College and Hospital.5 The inclusion and exclusion criteria for
this study is noted in Table 1. The primary efficacy outcome was reduction in pain from baseline
at 3 weeks and at 3 months following a PRP, CS, or placebo injection utilizing the VAS and the
American Orthopaedic Foot and Ankle Society (AOFAS) Ankle and Hindfoot score.5 This study
included 75 patients with chronic plantar fasciitis and randomly divided these patients into three
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groups evenly.5 Each injection was given at the patient’s point of maximal tenderness in the
heel.5 The PRP injection was prepared with 27 mL of autologous blood combined with 3 mL of
citrate dextrose solution and then centrifuged at 3200 RCF for 12 minutes, creating 2.5 to 3 mL
of PRP.5 2 mL of 40 mg of methylprednisolone was used for the CS injections and the placebo
group received normal saline.5 In both the PRP and CS groups, mean VAS score decreased
significantly from pre-injection baseline scores with no significant difference in pain in the
placebo group at 3 weeks follow-up and 3 months follow-up.5 However, at 3 weeks follow-up the
CS group received better outcome scores compared to the PRP group and at 3 months the PRP
groups received better outcome scores compared to the CS group, but this difference was
determined to not be significant.5 There were no adverse events reported by patients included in
this study.5
Table 4: Efficacy in Pain Reduction Evaluated by Mean Change in VAS in Mahindra et al.
Pre-injection
3 weeks
3 months
p-value
Platelet-Rich
7.44±1.04
3.76±1.53
2.52±1.71
<0.05
Plasma (PRP)
Corticosteroid
7.72±1.17
2.84±1.46
3.64±1.62
<0.05
(CS)
Placebo (normal 7.56±1.15
7.12±1.12
7.44±1.04
<0.05
saline)
DISCUSSION
Musculoskeletal injuries are common conditions in the United States and will continue to
be in the future. Therefore, it is important to determine the method of treatment that is most
beneficial to patients in the reduction of their pain due to these injuries. Both CS injections and
PRP injections are widely used treatment modalities for these such injuries today.
Forogh et al. determined that pain relief from PRP injections was significantly greater
than pain relief in those that were treated with corticosteroids.3 Krogh et al. concluded that there
was no significant difference in reduction of pain at 3 months follow-up when comparing PRP
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and CS to placebo.4 However, Krogh et al. was able to determine that CS was associated with
significant short term relief of pain at one month follow up.4 Mahindra et al. determined that both
PRP and CS injections were effective in reducing pain at three weeks and three months follow
up, however, PRP had significant better outcomes at three months follow up compared to CS
threapy.5
Whereas CS injections are more likely to be covered by insurance, such as Medicare,
PRP injections are not due to the lack of evidence of this newer procedure.10,11 Therefore, PRP
injections can range anywhere from $500 to $2000 without insurance coverage.10 CS injections
can range from $3 to $200.11 Costs of these injections can vary according to location and the
practitioner performing the injection.11
Uses for CS and PRP injections include inflammatory arthridities, tendinopathies, and
nerve compression syndromes with lack of evidence for various conditions.12 Contraindications
of both CS and PRP injections include periarticular infections, fractures, instability, septic
arthritis, certain locations on the body, and juxta articular osteoporosis.12 Complications due to
these injections are very uncommon and may just be due to administration error.12 CS and PRP
injections are both approved by the FDA.13,14 However, there use of CS epidural spinal injections
is not approved as well as several different PRP preparation systems.13,14
Evaluation of data was limited due to small sample sizes, the allowance of individuals to
drop out if not satisfied, differing prior treatments to trials, activity level post injections, and
exact preparations of the PRP injections.3,4,5 It is also essential to take note that these studies took
place in countries other than the United States. Treatments including other ethnicities would be
beneficial in determining if PRP is more effective in reducing pain for the general population of
the United States. All three studies also did not evaluate the reduction of pain greater than one
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year following the injections, allowing this to be another limitation due to the lack of long-term
efficacy in pain reduction.3,4,5
CONCLUSION
Based on the results of this review, the data is conflicting in whether or not PRP
injections reduce pain greater that CS injections in musculoskeletal injuries.3,4,5 While all three
studies reported pain reduction with both the PRP and CS injections, it is unclear which is more
effective in general.3,4,5 Evaluation of a longer duration would be beneficial in determining the
reduction of pain long-term following either PRP or CS injections. Future studies can utilize a
more specific pain rating scale for an injury to that specific structure that is being evaluated
rather than a generalized pain scale utilized for all injuries for more accurate results in pain
reduction. It may also be beneficial to educate patients in the trial that it may take time for the
injection to become effective to prevent withdrawal due to dissatisfaction. In conclusion, these
three studies indicated that PRP is an effective treatment for musculoskeletal injuries, however, a
larger sample size, longer duration, and more specific pain scale is needed to completely
determine its effectiveness when compared to CS injections.
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